IL4 and Alzheimer disease: Dupilumab, a monoclonal antibody targeting IL-4/IL-13 receptor signaling, has demonstrated significant efficacy in AD and AA, particularly in patients with an atopic backgrounds and elevated IgE levels (113–116).